CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$13.37M
Enterprise Value$11.76M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.10
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.38
Price to Sales (P/S)48.89
P/FCF Ratio-3.55
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue31.46
Enterprise Value/Gross Profit-32.29
Enterprise Value/Ebitda-3.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressAdvancing Phase I trials and external research ties indicate tangible R&D progression and a de-risking path for future productization. Over 2–6 months, dose escalation, multi-site enrollment and high-quality collaborations strengthen the company's ability to generate clinical data that underpins long-term commercialization potential.
Improved Leverage And CapitalizationA materially improved leverage profile and larger equity base provide the company more financial flexibility to fund R&D or absorb near-term losses. This reduced solvency risk makes it easier to negotiate financing, partnerships or execute strategic initiatives over the medium term without immediate solvency pressure.
Owned Production Assets And Low-cost Regional InfrastructureOwning production properties and leveraging regional, lower-cost operations supports durable operating leverage and lowers marginal manufacturing costs. These tangible assets and localized infrastructure can extend runway, enable scalable manufacturing and make partnerships or commercial rollouts in Asia more feasible over time.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow and a steep cash decline materially increase financing dependency. Over months, this raises the likelihood of dilutive capital raises or restrictive financing terms, pressuring strategic optionality and potentially slowing clinical or commercial initiatives without new funding.
Consistent Operating Losses And Volatile, Small RevenuePersistent net and operating losses against a tiny, inconsistent revenue base signal weak unit economics and limited internal cash generation. This structural profitability gap constrains reinvestment capacity and makes sustained R&D and commercial scaling contingent on external capital or major strategic partnerships.
Board-authorized Share Issuance / Dilution RiskBoard authority to issue equity and instruments institutionalizes the route for near-term fundraising. For a firm with limited cash and recurring losses, this raises a durable dilution risk that can change ownership structure and reduce per-share economics for existing holders absent clear, accretive uses of proceeds.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $13.37M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Technical Analysis
Ownership Overview
29.51% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
70.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---